[1]贾 敏,王龙胜.乳腺背景实质强化与乳腺癌不同分子亚型相关性研究[J].医学信息,2024,37(07):78-82.[doi:10.3969/j.issn.1006-1959.2024.07.014]
　JIA Min,WANG Long-sheng.Correlation Between Background Parenchymal Enhancement and Different Molecular Subtypes of Breast Cancer[J].Journal of Medical Information,2024,37(07):78-82.[doi:10.3969/j.issn.1006-1959.2024.07.014]
点击复制

乳腺背景实质强化与乳腺癌不同分子亚型相关性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年07期
页码:
78-82
栏目:
论著
出版日期:
2024-04-01

文章信息/Info

Title:
Correlation Between Background Parenchymal Enhancement and Different Molecular Subtypes of Breast Cancer
文章编号:
1006-1959（2024）07-0078-05
作者:
贾 敏; 王龙胜
（1.安徽医科大学第二附属医院影像科，安徽 合肥 230601；2.安徽医科大学附属六安医院磁共振室，安徽 六安 237005）
Author(s):
JIA Min; WANG Long-sheng
(1.Department of Imaging,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,Anhui,China;2.MRI Room,Lu’an Hospital Affiliated to Anhui Medical University,Lu’an 237005,Anhui,China)
关键词:
乳腺癌; 背景实质强化; 分子亚型
Keywords:
Breast cancer; Background parenchymal enhancement; Molecular subtype
分类号:
R445.2；R737.9
DOI:
10.3969/j.issn.1006-1959.2024.07.014
文献标志码:
A
摘要:
目的 探讨乳腺背景实质强化（BPE）与乳腺癌不同分子亚型的相关性。方法 回顾性分析2019年10月-2023年3月就诊于安徽医科大学附属六安医院的57例乳腺癌患者动态增强磁共振第一期BPE水平，依据第五版乳腺影像与数据系统（BIRADS）将BPE分为4型，即a型（极少强化）、b型（轻度强化）、c型（中度强化）、d型（显著强化）。根据免疫组化标志物雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体-2（HER-2）、细胞增殖的相关抗原Ki-67表达结果，将乳腺癌分为4种亚型：Luminal A型、Luminal B型、HER-2过表达型及三阴性型。比较BPE水平与乳腺癌不同免疫组化标志物及分子亚型间差异，分析BPE水平与年龄、绝经状态的相关性。结果 57例乳腺癌患者中，Luminal A型17例，Luminal B型21例，HER-2过表达型12例，三阴性7例。BPE水平与年龄呈负相关（r=-0.299，P=0.024），与绝经状态呈负相关（r=-0.398，P=0.002）；乳腺癌免疫组化标志物PR与定性BPE有关（P=0.043），乳腺癌免疫组化标志物ER、HER-2、Ki-67及四种不同分子亚型与定性BPE无关。结论 BPE有可能作为乳腺癌预后评估的影像学标志，为乳腺癌的治疗提供指导。
Abstract:
Objective To explore the correlation between background parenchymal enhancement (BPE) and different molecular subtypes of breast cancer.Methods The first phase BPE levels of 57 patients with breast cancer who were admitted to Lu ’an Hospital Affiliated to Anhui Medical University from October 2019 to March 2023 were retrospectively analyzed. According to the fifth edition of the Breast Imaging and Reporting Data System (BIRADS), BPE was classified into four types: type a (minimal enhancement), type b (mild enhancement), type c (moderate enhancement), and type d (significant enhancement). According to the expression results of the immunohistochemical markers estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER-2), and cell proliferation related antigen Ki-67, breast cancer was divided into four subtypes: Luminal A, Luminal B, HER-2 overexpression and triple negative. The differences between BPE levels and different immunohistochemical markers and molecular subtypes of breast cancer were compared, and the correlation between BPE levels and age and menopausal status was analyzed.Results Among 57 cases of breast cancer, 17 cases were Luminal A type, 21 cases were Luminal B type, 12 cases were HER-2 overexpression type, and 7 cases were triple negative. The level of BPE was negatively correlated with age (r=-0.299, P=0.024) and menopausal status (r=-0.398, P=0.002). The immunohistochemical marker PR of breast cancer was related to qualitative BPE (P=0.043). The immunohistochemical markers ER, HER-2, Ki-67 and four different molecular subtypes of breast cancer were not related to qualitative BPE.Conclusion BPE may be used as an imaging marker for evaluating the prognosis of breast cancer and provide guidance for the treatment of breast cancer.

参考文献/References:

[1]Thompson JL,Wright GP.The role of breast MRI in newly diagnosed breast cancer: an evidence-based review[J].The American Journal of Surgery,2021,221(3):525-528.[2]何思怡,李贺,曹毛毛,等.全球及我国女性乳腺癌疾病负担年龄分布及变化趋势[J].中国肿瘤,2023,32(1):1-7.[3]国家肿瘤质控中心乳腺癌专家委员会.中国乳腺癌规范诊疗质量控制指标(2022 版)[J].中华肿瘤杂志,2022,44(3):203-208.[4]蒋新华,李姣,蔡宏民,等.乳腺癌MRI影像组学特征与分子标记物的相关性研究[J].放射学实践,2019,34(2):152-156.[5]Choi SY,Chang YW,Park HJ,et al.Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer[J].The British Journal of Radiology,2012,85(1016):e474-e479.[6]Sun K,Chen X,Chai W,et al.Breast cancer: diffusion kurtosis MR imaging-diagnostic accuracy and correlation with clinical-pathologic factors[J].Radiology,2015,277(1):46-55.[7]Sippo DA,Rutledge GM,Mercaldo SF,et al.Impact of Background Parenchymal Enhancement on Diagnostic Performance in Screening Breast MRI[J].Academic Radiology,2020,27(5):663-671. [8]Sung JS,Corben AD,Brooks JD,et al.Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI[J].Breast Cancer Research and Treatment,2018,172(2):487-496.[9]Dontchos BN,Rahbar H,Partridge SC,et al.Influence of Menstrual Cycle Timing on Screening Breast MRI Background Parenchymal Enhancement and Diagnostic Performance in Premenopausal Women[J].Journal of Breast Imaging,2019,1(3):205-211. [10]Heller SL,Young Lin LL,Melsaether AN,et al.Hormonal Effects on Breast Density, Fibroglandular Tissue, and Background Parenchymal Enhancement[J].Radiographic,2018,38(4):983-966.[11]Sippo DA,Rutledge GM,Burk KS,et al.Effect of background parenchymal enhancement on cancer risk across different high-risk patient populations undergoing screening breast MRI[J].American Journal of Roentgenology,2019,212(6):1412-1418.[12]黄伟忠.乳腺癌不同分子分型和临床病理特征对预后的影响[J].包头医学院学报,2018,34(1):43-44.[13]Dilorenzo G,Telegrafo M,La Forgia D,et al.Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type[J].European Journal of Radiology,2019,113:148-152.[14]Ha R,Mango V,Al-Khalili R,et al.Evaluation of association between degree of background parenchymal enhancement on MRI and breast cancer subtype[J].Clinical Imaging,2018,51:307-310.[15]Lim Y,Ko ES,Han BK,et al.Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer[J].Breast Cancer Research and Treatment,2017,163(3):573-586.[16]Mema E,Schnabel F,Chun J,et al.The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer[J].European Journal of Radiology,2020,124:108813.[17]Brooks JD,Sung JS,Pike MC,et al.MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women[J].International Journal of Cancer,2018,143(4):823-830.[18]Johansson ALV,Trewin CB,Fredriksson I,et al.In modern times, how important are breast cancer stage, grade and receptor subtype for survival:a population-based cohort study[J].Breast Cancer Research,2021,23(1):1-10.[19]?魻ztürk M,Polat AV,Süllü Y,et al.Background parenchymal enhancement and fibroglandular tissue proportion on breast MRI:correlation with hormone receptor expression and molecular subtypes of breast cancer[J].Journal of Breast Health,2017,13(1):27.[20]Li J,Mo Y,He B,et al.Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer[J].British Journal of Radiology,2019,92(1103):20190417.[21]尤超,顾雅佳,胡晓欣,彭卫军.乳腺背景实质强化对乳腺癌分子分型评估的价值[J].肿瘤影像学,2020,29(2):79-84.[22]Watt GP,Sung J,Morris EA,et al.Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study[J].Breast Cancer Research,2020,22(1):138.[23]Szep M,Pintican R,Boca B,et al.Multiparametric MRI features of breast cancer molecular subtypes[J].Medicina,2022,58(12):1716-1716.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(07):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(07):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(07):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘雪静,路 红,徐熠琳,等.乳腺影像与容积导航技术初步应用的临床分析[J].医学信息,2022,35(11):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
　LIU Xue-jing,LU Hong,XU Yi-lin,et al.Clinical Analysis of the Preliminary Application of Breast Imaging and Volume Navigation Technology[J].Journal of Medical Information,2022,35(07):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
[6]刘在波,修文娟.背阔肌皮瓣联合假体在乳腺癌改良根治术后乳房重建中的应用[J].医学信息,2019,32(02):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
　LIU Zai-bo,XIU Wen-juan.Application of Latissimus Dorsi Flap Combined with Prosthesis in Breast Reconstruction after Modified Radical Mastectomy for Breast Cancer[J].Journal of Medical Information,2019,32(07):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
[7]孟庆国,王佳雪,王斯佳.马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J].医学信息,2019,32(02):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
　MENG Qing-guo,WANG Jia-xue,WANG Si-jia.Effect of Pyrrolidine Maleate on Cardiac Function in Patients after Breast Cancer Operation[J].Journal of Medical Information,2019,32(07):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
[8]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(07):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[9]满枋霖,葛俊宏,林晓月,等.p21活化激酶在乳腺癌中的作用研究[J].医学信息,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
　MAN Fang-lin,GE Jun-hong,LIN Xiao-yue,et al.The Role of p21 Activated Kinase in Breast Cancer[J].Journal of Medical Information,2019,32(07):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
[10]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
　ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Journal of Medical Information,2019,32(07):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]

更新日期/Last Update: 1900-01-01